Previous close | 2.6600 |
Open | 2.7804 |
Bid | 2.5100 x 100 |
Ask | 0.0000 x 0 |
Day's range | 2.7804 - 2.7804 |
52-week range | 1.3300 - 3.2900 |
Volume | |
Avg. volume | 30,777 |
Market cap | 28.287M |
Beta (5Y monthly) | 1.39 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.6200 |
Earnings date | 12 Aug 2024 - 16 Aug 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 10.00 |
BOTHELL, Wash., June 20, 2024 (GLOBE NEWSWIRE) -- Cocrystal Pharma, Inc.’s (Nasdaq: COCP) novel, broad-spectrum antiviral CC-42344 inhibits activity in the highly pathogenic avian influenza A (H5N1) PB2 protein recently identified in infected dairy cattle, according to recently completed in vitro studies. CC-42344 is a new class of antiviral drugs designed to block essential steps in the replication and transcription of the influenza A virus. Cocrystal is conducting an influenza A Phase 2a clini
When a stock experiences a golden cross technical event, good things could be on the horizon. How should investors react?
Topline single ascending dose (SAD) Phase 1 results of oral CDI-988, the first potential pan-coronavirus-pan-norovirus oral antiviral, expected in the second quarter of 2024 Enrollment completed in Phase 2a influenza A human challenge study of oral CC-42344, with topline results expected in the second half of 2024FDA pre-IND feedback for oral CC-42344 received in first quarter of 2024 provides better clarity on late-stage trial designInitiation of Phase 1 study of inhaled CC-42344, a potential i